Literature DB >> 19912295

Outcome evaluation in glioblastoma patients using different ranking scores: KPS, GOS, mRS and MRC.

A M Stark1, W Stepper, H M Mehdorn.   

Abstract

Patient performance is an overall accepted independent prognostic factor in glioblastoma patients. Its estimation is essential for treatment planning, follow-up and clinical trials. Patient performance is mostly determined by usage of the Karnofsky Performance Score (KPS) for cancer patients. However, several other ranking scores have been developed specifically for patients with neurological diseases: Glasgow Outcome Score (GOS) for trauma patients, modified Ranking Score for stroke patients and Medical Research Council brain prognostic index (MRC) for brain tumour patients. The aims of this study were: (1) to compare these four performance scores in their ability to determine patient survival; and (2) to compare the prognostic value of performance with that of other prognostic factors. Univariate and multivariate survival analysis was used. Survival analysis revealed a high correlation to survival for all four scores. The maximum derivation of the curves was shown for the MRC and GOS. Performance had more clinical impact in determining patient survival than age and tumour resection. Differential treatment planning may need the formation of more than two patient groups. This was possible with the MRC, as well as the GOS and KPS. Forming more than three patient groups was not effective with any score.

Entities:  

Mesh:

Year:  2009        PMID: 19912295     DOI: 10.1111/j.1365-2354.2008.00956.x

Source DB:  PubMed          Journal:  Eur J Cancer Care (Engl)        ISSN: 0961-5423            Impact factor:   2.520


  21 in total

1.  Hyperglycemia is independently associated with post-operative function loss in patients with primary eloquent glioblastoma.

Authors:  Thomas W Link; Graeme F Woodworth; Kaisorn L Chaichana; Stuart A Grossman; Robert S Mayer; Henry Brem; Jon D Weingart; Alfredo Quinones-Hinojosa
Journal:  J Clin Neurosci       Date:  2012-05-15       Impact factor: 1.961

2.  The relative value of postoperative versus preoperative Karnofsky Performance Scale scores as a predictor of survival after surgical resection of glioblastoma multiforme.

Authors:  Lola B Chambless; Heather M Kistka; Scott L Parker; Laila Hassam-Malani; Matthew J McGirt; Reid C Thompson
Journal:  J Neurooncol       Date:  2014-10-26       Impact factor: 4.130

Review 3.  Clinical outcome assessment in malignant glioma trials: measuring signs, symptoms, and functional limitations.

Authors:  Jaishri O Blakeley; Stephen Joel Coons; John R Corboy; Nancy Kline Leidy; Tito R Mendoza; Jeffrey S Wefel
Journal:  Neuro Oncol       Date:  2016-03       Impact factor: 12.300

4.  Early measures of cognitive function predict survival in patients with newly diagnosed glioblastoma.

Authors:  Derek R Johnson; Allison M Sawyer; Christina A Meyers; Brian Patrick O'Neill; Jeffrey S Wefel
Journal:  Neuro Oncol       Date:  2012-04-16       Impact factor: 12.300

5.  Evolution of the Karnosky Performance Status throughout life in glioblastoma patients.

Authors:  Adama Sacko; Miao-Miao Hou; Michael Temgoua; Ali Alkhafaji; Athina Marantidou; Catherine Belin; Emmanuel Mandonnet; Renata Ursu; Jennifer Doridam; Irène Coman; Christine Levy-Piedbois; Antoine F Carpentier
Journal:  J Neurooncol       Date:  2015-02-21       Impact factor: 4.130

6.  Post-surgical therapeutic approaches to glioblastoma patients submitted to biopsy (BA) or "partial" resection (PR): the possibilities to treat also them without renunciations. Study from the Brescia Neuro-Oncology Group.

Authors:  Michela Buglione; Paolo Borghetti; Sara Pedretti; Luca Triggiani; Marco Maria Fontanella; Giannantonio Spena; Salvatore Grisanti; Roberto Liserre; Luigi Pietro Poliani; Stefano Gipponi; Luigi Spiazzi; Stefano Maria Magrini
Journal:  Radiol Med       Date:  2015-03-15       Impact factor: 3.469

Review 7.  Surgical resection of malignant gliomas-role in optimizing patient outcome.

Authors:  Ilker Y Eyüpoglu; Michael Buchfelder; Nic E Savaskan
Journal:  Nat Rev Neurol       Date:  2013-01-29       Impact factor: 42.937

8.  The Added Prognostic Value of Preoperative Dynamic Contrast-Enhanced MRI Histogram Analysis in Patients with Glioblastoma: Analysis of Overall and Progression-Free Survival.

Authors:  Y S Choi; D W Kim; S-K Lee; J H Chang; S-G Kang; E H Kim; S H Kim; T H Rim; S S Ahn
Journal:  AJNR Am J Neuroradiol       Date:  2015-09-03       Impact factor: 3.825

9.  PTEN mutations predict benefit from tumor treating fields (TTFields) therapy in patients with recurrent glioblastoma.

Authors:  Antonio Dono; Sonali Mitra; Mauli Shah; Takeshi Takayasu; Jay-Jiguang Zhu; Nitin Tandon; Chirag B Patel; Yoshua Esquenazi; Leomar Y Ballester
Journal:  J Neurooncol       Date:  2021-04-21       Impact factor: 4.130

Review 10.  Endovascular versus Non-Interventional Therapy for Cervicocranial Artery Dissection in East Asian and Non-East Asian Patients: a Systematic Review and Meta-analysis.

Authors:  Rongzhong Huang; Lingchuan Niu; Ying Wang; Gongwei Jia; Lang Jia; Yule Wang; Wei Jiang; Yang Sun; Lehua Yu
Journal:  Sci Rep       Date:  2015-05-20       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.